secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2021-07-12T23:59:59+00:00
Accession:  0001193125-21-212534
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics appoints Nicholas Maestas as VP, Strategy and Finance and PFO
--------------------------------------------------------------------------------

- Appointed Nicholas Maestas, age 41, as VP, Strategy and Finance and principal financial officer, effective July 12, 2021.
- Maestas previously served as head of FP&A and strategic finance at Alector, Inc. since 2019.
- Base salary of $325,000; eligible for annual performance bonus with target of 30% of base salary.
- Granted option to purchase 23,225 common shares at July 12 closing price; vests 25% at 1 year, then monthly over 48 months.
- Severance: 3 months salary/benefits outside change of control; 6 months salary plus 50% bonus and accelerated vesting during change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521212534/0001193125-21-212534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521212534/d181625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-212534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer